Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01087125 · ClinicalTrials.gov registry record
Abatacept Pregnancy Exposure Registry
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 42
- Enrollment target
NCT01087125 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 42 participants.
The verdict
NCT01087125 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
The purpose of the abatacept pregnancy registry is to monitor planned and unplanned pregnancies exposed to abatacept, to evaluate the possible teratogenic effects (that is, any abnormal development) of this medication in the pregnancy outcome and to follow live born infants for one year after birth.
Interventions
- DRUG No Interventions
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2006-09-01 |
| Est. Completion | 2019-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01087125
The ClinicalTrials.gov registry entry for NCT01087125 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Interventions is the first listed.
NCT01087125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01087125 about?
NCT01087125 is a clinical study titled "Abatacept Pregnancy Exposure Registry". The purpose of the abatacept pregnancy registry is to monitor planned and unplanned pregnancies exposed to abatacept, to evaluate the possible teratogenic effects (that is, any abnormal development) of this medication in the pregnancy outcome and to follow live born infants for one year after birth.
What is the current status of trial NCT01087125?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2006-09-01. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT01087125?
The interventions under investigation include: No Interventions (DRUG).
Who is sponsoring clinical trial NCT01087125?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.